Parallel Bio
ActiveUsing the immune system to cure disease
This company has previously operated under “Parallel Biosystems Inc”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development. Parallel Bio’s platform overcomes the core limitations of traditional animal testing, which fails to encapsulate the complexity of human biology. The company is building internal pipelines of novel disease targets and drug candidates in both cancer and autoimmune disease, while collaborating with pharmaceutical companies to evaluate therapies directly in human systems to reduce the cost and risk of clinical trials. Based in San Francisco, the company was founded in 2021 by two of the world’s leading experts in replacing animal models with human-first platforms.
Founders · 2
Robert is a co-founder and CEO of Parallel Bio. Previously he was Director of Strategy & Research Development at Stanford University where he oversaw a $100M scientific portfolio and ran 8 large-scale R&D programs. He also worked in global health and ran vaccine programs with GSK, the NIH, and the Danish government. He completed his postdoctoral training at Stanford, holds a PhD from the University of Pittsburgh, and a BS from the University of Illinois.
Juliana is a co-founder and the CSO of Parallel Bio. She previously worked at System1 Biosciences managing R&D brain organoid drug discovery teams and has extensive experience developing mini-organ systems to better model human disease and discover new drugs.
Related startups
PipeBio is a SaaS bioinformatics platform to develop antibody drugs.
Multi-targeted therapeutics to treat complex diseases
